Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation
- 65 Downloads
Relatively few reports on the clinical impact of atrial fibrillation (AF) in hypertrophic obstructive cardiomyopathy (HOCM) are available. The aims of our study are to report the effect of transcoronary ablation of septal hypertrophy (TASH) on clinical outcome in HOCM associated with AF and to evaluate the influence of AF on symptoms and quality of life in HOCM.
Patient and methods
In 80 consecutive patients (38 f, mean age 56 ± 17 years) with severely symptomatic HOCM referred for interventional treatment, we analyzed the prevalence of AF based on 240 Holter ECG recordings and patients’ history, retrospectively. Symptoms, quality of life, number of hospital admissions and hemodynamic performance were obtained in all patients before and after TASH. Mortality was additionally investigated by letter and telephone contact.
The overall prevalence of AF was 29%. Paroxysmal AF was detected in 17 pts (21.3%), persistent AF in 5 pts (6.3%). Only 1 pt (1.3%) suffered from permanent AF. Symptoms due to AF were present in 52.6% of the AF patients. Quality of life score was markedly improved after TASH (15.9 ± 3.8 vs. 20.7 ± 3.8, p < 0.001) with no difference between sinus rhythm and atrial fibrillation. However, hospital admissions were more frequent in the AF group (0.85 ± 1.84 vs. 0.28 ± 0.81, p = 0.03) in 32 ± 13 months. AF patients suffered more often from syncope before TASH (30 ± 70% vs. 10 ± 30%, p = 0.008). Two patients with sinus rhythm at baseline died after 32 ± 13 months from cardiovascular cause.
Atrial fibrillation is the major cardiac arrhythmia in severe HOCM. The majority of AF patients demonstrate AF specific symptoms. The paroxysmal type of atrial fibrillation dominates by far. Both patients with and without atrial fibrillation showed similar quality of life with marked improvement after TASH.
Key wordsHypertrophic obstructive cardiomyopathy atrial fibrillation transcoronary alcohol ablation of septal hypertrophy
Unable to display preview. Download preview PDF.
- 6.Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boeckstegers P, Neuhaus L, Seipel L, Horstkotte (2005) Catheterbased septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Follow–up results of the TASHregistry of the German Cardiac Society. Z Kardiol 94:516–523CrossRefPubMedGoogle Scholar
- 10.Gietzen FH, Leuner ChJ, Raute–Kreinsen U, Dellmann A, Hegselmann J, Strunk–Mueller C, Kuhn HJ (1999) Acute and long–term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic cardiomyopathy. Eur Heart J 20:1342–1354CrossRefPubMedGoogle Scholar
- 11.Gietzen FH, Leuner CJ, Obergassel L, Strunk–Mueller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Assocociation functional class III and IVand outflow obstruction only under provocable conditions. Circulation 106(4):454–459CrossRefPubMedGoogle Scholar
- 13.Kuhn H, Gietzen FH, Leuner Ch, Schäfers M, Schober O, Strunk–Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Reite–Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4:IV):41–54Google Scholar
- 16.Kuhn H, Lawrenz T, Lieder F, Gietzen F, Obergassel L, Strunk–Mueller C, Stolle B, Leuner CJ (2004) Alcohol septal ablation in the treatment of hypertrophic obstructive cardiomyopathy: a seven–year experience. In: Maron BJ (ed) Diagnosis and Management of Hypertrophic Cardiomyopathy, 1st edn. Blackwell Futura, Malden, pp 279–296Google Scholar
- 17.Lawrenz Th, Obergassel L, Lieder F, Leuner Ch, Strunk–Mueller C, Meyer zu Vilsendorf D, Beer G, Kuhn H (2005) Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. PACE 28:1–6Google Scholar
- 20.Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, TenCate FJ, Wigle ED (2003) American college of cardiology/ european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24:1965–1991CrossRefPubMedGoogle Scholar
- 21.Obergassel L, Gietzen FH, Strunk– Mueller C, Meyer zu Vilsendorf D, Lawrenz T, Bartelsmeier, Kuhn HJ (2001) Does Transcoronary Ablation of Septal Hypertrophy (TASH) in Hypertrophic Cardiomyopathy (HOCM) Induce an Arrhythmogenic Substrate? Clinical Results and Holter–ECG–Data. PACE 24(4):694Google Scholar
- 22.Obergassel L, Lawrenz Th, Meyer zu Vilsendorf D, Gietzen FH, Strunk– Mueller C, Kuhn H (2001) His–Bündel– Ablation (HBA) bei hypertrophisch– obstruktiver Kardiomyopathie (HOCM) und tachykardem Vorhofflimmern. Z Kardiol 90(Suppl 5):V/76Google Scholar
- 23.Obergassel L, Lawrenz T, Gietzen FH, Strunk–Mueller C, Kuhn H (2002) Atrial fibrillation in hypertrophic obstructive cardiomyopathy: prevalence, symptoms and quality of live. Eur H Jour 23(Abstr Suppl):487Google Scholar
- 29.Ueng KC, Tsai TP, Tsai CF, Wu DJ, Lin CS, Lee SH, Chen SA (2001) Acute and long–term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 12:303–309CrossRefPubMedGoogle Scholar